Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86.

View in: PubMed

subject areas

Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Bevacizumab
Fallopian Tube Neoplasms
Fallopian Tube Neoplasms
Female
Female
Humans
Humans
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Ovarian Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms
Peritoneal Neoplasms
Stilbenes
Stilbenes

authors with profiles

Joan L Walker